MCM
GILD icon

Moore Capital Management’s Gilead Sciences GILD Stock Holding History

Moore Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-90,000
Closed -$9.99M – 732
2025
Q3 		$9.99M Buy
+90,000
New +$10.2M 0.14% 152
2013
Q3 		– Sell
-150,000
Closed -$7.69M – 384
2013
Q2 		$7.69M Buy
+150,000
New +$7.82M 0.18% 105

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Moore Capital Management's GILD Position: Q1 2023 in Review

Moore Capital Management sold out of Gilead Sciences (GILD) in Q1 2023, closing a stake of 65,000 shares — an estimated $5.58M sold.

Moore Capital Management first reported a position in GILD in Q2 2013 and held it in 13 quarters. The position peaked at $159M in Q1 2014. 1,735 funds tracked by Wall St. Rank hold GILD as of Q1 2023.

  • Moore Capital Management reported no remaining Gilead Sciences position as of Q1 2023 after selling out during the quarter.
  • Moore Capital Management sold 65,000 Gilead Sciences shares in Q1 2023, an estimated $5.58M.
  • Moore Capital Management first reported a position in Gilead Sciences in Q2 2013 and held it in 13 quarters.
  • Moore Capital Management's Gilead Sciences position peaked at $159M in Q1 2014.
  • 1,735 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2023.

Based on Moore Capital Management's 13F filing for Q1 2023, filed 15 May 2023.